Journal of Oncology Pharmacy Practice最新文献_第3页

Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice. 2015 至 2020 年日本药剂师参与癌症护理的趋势分析：全国医院药学实践调查研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-07-25 DOI: 10.1177/10781552241263997

Masami Tsuchiya, Daisuke Kikuchi, Shiro Hatakeyama, Yuichi Tasaka, Takeshi Uchikura, Ryohkan Funakoshi, Taku Obara

{"title":"Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice.","authors":"Masami Tsuchiya, Daisuke Kikuchi, Shiro Hatakeyama, Yuichi Tasaka, Takeshi Uchikura, Ryohkan Funakoshi, Taku Obara","doi":"10.1177/10781552241263997","DOIUrl":"10.1177/10781552241263997","url":null,"abstract":"IntroductionPharmacists are needed as members of oncology teams. The Japanese Society of Hospital Pharmacists (JSHP) conducts a nationwide survey annually to analyze the actual situation and generate fundamental information about hospital pharmacy practice in Japan. Using data from this large-scale survey, we described pharmacists' involvement in cancer chemotherapy. We explored the factors related to the acceleration of pharmacists' tasks or involvement in clinical practice, primarily in oncology.MethodsData were obtained from annual surveys conducted by JSHP from 2015 to 2020. All variables were expressed as categorical variables and tabulated. The Chi-square and Fisher's exact tests were used to compare the categorical variables. The Cochran-Armitage trend test was used to identify significant trends.ResultsFrom 2015 to 2020, 22,362 responses were recorded. After applying the exclusion criteria, 20,906 were analyzed. The proportion of hospitals enrolling pharmacists with oncology-related certifications significantly increased in all hospitals providing cancer care. Multivariable logistic regression analysis indicated that a smaller number of beds per pharmacist significantly correlated with additional fees for outpatient pharmacy services (p = 0.0002 for trend).ConclusionHospitals charging increased fees for outpatient oncology pharmacy services were associated with a smaller number of beds per pharmacist, regardless of hospital size. A balance between the number of beds and pharmacists, particularly certified oncology pharmacists, is crucial for safe and high-quality cancer treatment.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"803-809"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A study to quantify knowledge obtained during the British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) Course. 对英国肿瘤药学协会 (BOPA) 肿瘤学入门 (ITO) 课程中获得的知识进行量化研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-06-05 DOI: 10.1177/10781552241259367

Netty Cracknell, Catherine Parbutt, Clayton Wong, Tasneem Ganijee

{"title":"A study to quantify knowledge obtained during the British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) Course.","authors":"Netty Cracknell, Catherine Parbutt, Clayton Wong, Tasneem Ganijee","doi":"10.1177/10781552241259367","DOIUrl":"10.1177/10781552241259367","url":null,"abstract":"IntroductionThe British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) course has run for over 20 years. The ITO course is provided free of charge to BOPA PAID members, and there was an increase in cost moving to a two-day event in 2023. The BOPA Education and Training (E&T) subcommittee and BOPA Executive Committee wanted to validate that the course was meeting its objective of improving the baseline knowledge of the pharmacists and pharmacy technicians attending, and therefore justifying the increased cost to BOPA and employing organisations.MethodDuring the ITO course in November 2023, quantitative data was collected using a questionnaire-based survey with 5-point Likert scales. This was administered to delegates at the start of each respective day to assess baseline knowledge level. Another survey was administered at the end of each respective day to re-assess knowledge level.ResultsThere is a positive overall change for all sessions. This ranged from a + 0.92 to +1.76 improvement across the board. This was applicable regardless of profession. For all responders the greatest improvement of knowledge was seen in A. 'Extravasation of SACT' session (+1.76), 'Oncological Emergencies' (+1.51) and 'The cancer patient pathway' (+1.51) B. those with less than 6 months experience (+1.54).ConclusionThis study has demonstrated that overall the ITO course improved the baseline knowledge of the delegates attending the course (+1.21). The delegates were also more confident in verifying SACT prescriptions after the course.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"761-768"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug therapy problems among paediatric acute lymphoblastic leukaemia patients at Kenyatta National Hospital. 肯雅塔国立医院儿科急性淋巴细胞白血病患者的药物治疗问题。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-06-03 DOI: 10.1177/10781552241256811

Faith Jelagat Magut, Amsalu Degu

{"title":"Drug therapy problems among paediatric acute lymphoblastic leukaemia patients at Kenyatta National Hospital.","authors":"Faith Jelagat Magut, Amsalu Degu","doi":"10.1177/10781552241256811","DOIUrl":"10.1177/10781552241256811","url":null,"abstract":"IntroductionSeveral studies reported that drug therapy problems (DTPs) were prevalent in cancer patients. These DTPs are still interfering with the desired treatment outcomes in patients with cancer. This study aimed to determine the prevalence, types and predictors of DTPs among paediatric acute lymphoblastic leukaemia (ALL) patients at Kenyatta National Hospital.MethodsA retrospective cohort study was used to assess DTPs among ALL patients. Records of all eligible paediatric patients with ALL who received treatment in the facility between 1 January 2017 and 31 December 2021 were examined. A data abstraction tool was employed for data collection. The data entry and analysis were carried out by a statistical package for social sciences version 29.0 software. Frequency tables were utilised to present the key findings of the study. Binary logistic regression analysis was utilised to determine the predictors of DTPs.ResultsA total of 82 DTPs were identified with the most common type of DTP being adverse drug reaction (ADR; 59, 72.0%) and drug interaction (9, 11.0%). The most common ADRs identified were febrile neutropenia (20, 33.9%), nausea/vomiting (14, 23.7%) and anaemia (11, 18.6%). Patients with central nervous system disease (adjusted odds ratio [AOR] = 10.2, 95% CI = 1.2-85.8, p = 0.03) and treated with a combination of chemotherapy and radiotherapy (AOR = 13.5, 95% CI = 1.9-89.4, p = 0.01) were more likely to develop DTPs.ConclusionThe study found that the prevalence of DTPs among paediatric ALL patients was high, with the most common DTPs being ADRs occurring in 72.0% of patients. Central nervous system metastasis and a combination of chemotherapy and radiation treatment regimens were statistically significant predictors of DTPs.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"730-735"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Midostaurin-Associated acute pancreatitis. midoin相关性急性胰腺炎。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-12-05 DOI: 10.1177/10781552241304755

Mert Akyildiz, Nebi Cankat Geygel, Esma Hazal Burhan, Erdinc Gulumsek, Begum Seyda Avci, Huseyin Ali Ozturk, Fatih Necip Arici, Mehmet Bankir, Tayyibe Saler, Hilmi Erdem Sumbul

{"title":"Midostaurin-Associated acute pancreatitis.","authors":"Mert Akyildiz, Nebi Cankat Geygel, Esma Hazal Burhan, Erdinc Gulumsek, Begum Seyda Avci, Huseyin Ali Ozturk, Fatih Necip Arici, Mehmet Bankir, Tayyibe Saler, Hilmi Erdem Sumbul","doi":"10.1177/10781552241304755","DOIUrl":"10.1177/10781552241304755","url":null,"abstract":"IntroductionThe multikinase inhibitor midostaurin is the first targeted drug for the treatment of AML FLT3. It reduces mortality by 23% more than standard chemotherapy group. Although it has many gastrointestinal side effects, there is no data in the literature regarding its association with acute pancreatitis. We wanted to present an acute pancreatitis case that developed after midostaurin treatment in our clinic.Case ReportA patient with AML FLT3 who developed abdominal pain, elevated amylase-lipase enzymes and increased volume around the pancreas on abdominal imaging after the addition of midostaurin to chemotherapy was hospitalized with a prediagnosis of acute pancreatitis.Management & OutcomeOral feeding was stopped, intravenous hydration was provided and anti-symptomatic treatment was given. The patient was discharged on the 4th day of hospitalization after the acute pancreatitis clinic resolved.DiscussionDrug induced acute pancreatitis is a rare clinical condition which is difficult to diagnose. It has a good prognosis and low mortality rate. The mechanisms of drug-induced pancreatitis include immunological reactions, direct toxic effect, accumulation of toxic metabolites, overstimulation of pancreatic acinar cells, ischemia, intravascular thrombosis and increased viscosity of pancreatic secretion. Although there are many gastrointestinal side effects of midostaurin, there are no clear data in the literature regarding the relationship with acute pancreatitis.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"835-838"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report. 在过敏反应和转移性尿路上皮癌中对Avelumab的管理和脱敏：1例报告。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2025-02-13 DOI: 10.1177/10781552241313057

Rosalaura Villarreal-González, Ana Karen Treviño-Morales, Diana Cadenas-García, Ángel López-Galindo, Oscar Vidal-Gutiérrez

{"title":"Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.","authors":"Rosalaura Villarreal-González, Ana Karen Treviño-Morales, Diana Cadenas-García, Ángel López-Galindo, Oscar Vidal-Gutiérrez","doi":"10.1177/10781552241313057","DOIUrl":"10.1177/10781552241313057","url":null,"abstract":"IntroductionUrothelial carcinoma is the prevailing type of bladder cancer, characterized by expression of the programed death-ligand-1-protein (PD-L1). Avelumab is an anti-PD-L1 monoclonal antibody used in urothelial carcinoma. It is associated with an incidence of 47.4% and 25.2% in grade 3 adverse events or greater, respectively; gastrointestinal symptoms and cutaneous affections are the most common.Case reportA 52-year-old male with a history of rectal cancer and non-muscle-invasive bladder carcinoma. PET/CT revealed adenopathies in the pelvic region, the biopsy confirmed metastatic urothelial carcinoma. Next PET/CT indicated progression. Treatment with Cisplatin + Gemcitabine led to complete response after 4 cycles. Maintenance with Avelumab was indicated. Fifteen minutes after the first Avelumab administration, the patient experienced hypotension, presyncope, skin itching, and nasal congestion. Epinephrine, hydrocortisone, and physiological solution were administered, with resolution of symptoms.Management & outcomeSince Avelumab is first-line maintenance therapy in this patient, a desensitization protocol was performed with (3-bag, 12-steps). The patient was premedicated with acetaminophen and chlorpheniramine. The protocol was successfully completed without hypersensitivity reactions for 6 cycles.DiscussionPatients with hypersensitivity reactions to their first line of treatment are challenged to continue the best approach. We detail the case of a patient diagnosed with metastatic urothelial carcinoma who underwent a desensitization protocol for Avelumab after presenting a severe allergic reaction. The patient tolerated Avelumab throughout the protocol with no complications, achieving the total dosage for his maintenance therapy; drug desensitization is a safe and effective procedure in patients with hypersensitivity reactions to their first-line treatment.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"839-841"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions. 在治疗单克隆抗体相关输液反应引起的剧烈疼痛方面，美替利定与吗啡进行了比较。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-06-17 DOI: 10.1177/10781552241259986

Hanna Yakubi, Aaron Paul Steele, Megan Tsao

{"title":"Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions.","authors":"Hanna Yakubi, Aaron Paul Steele, Megan Tsao","doi":"10.1177/10781552241259986","DOIUrl":"10.1177/10781552241259986","url":null,"abstract":"IntroductionInfusion reactions, characterized by symptoms such as rigors, fever, and hypotension, are common adverse events that occur during monoclonal antibody (MAB) therapy. The treatment of rigors often involves opioids, most commonly meperidine, despite limited evidence supporting use in the setting of MAB infusions. This study aims to compare the efficacy and safety of intravenous (IV) meperidine and morphine is treatment of MAB-related rigors, filling a significant gap in the literature.MethodsThis was a single-center, retrospective cohort study which reviewed patients either inpatient or within outpatient infusion centers from January 2015 to January 2024. Patients receiving IV 2 mg morphine or 25 mg meperidine for MAB-related rigors were included. The primary outcome was defined as the number of opioid doses required for rigors ablation. Secondary outcomes included rates of naloxone administration and documented sedation.ResultsA total of 1251 administration events were screened, of which 127 and 26 rigor events were in the meperidine and morphine cohorts, respectively, were included. A majority of both cohorts required only one dose of either agent for rigors ablation with <20% of either cohort requiring 2 or more doses (p = 0.539). Low rates of sedation were observed in both groups.ConclusionBoth meperidine and morphine effectively manage MAB-related rigors within minimal safety concerns. These findings suggest that morphine is a suitable alternative to meperidine for this indication, which may influence future formulary decision, provide alternatives for drug shortage, and optimize supportive care for patients undergoing MAB therapy.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"775-779"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141331214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to caregiver-administered intravenous immunosuppressant medications in pediatric hematopoietic stem cell transplant. 小儿造血干细胞移植患者对护理人员静脉注射免疫抑制剂药物的依从性。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-05-31 DOI: 10.1177/10781552241258151

Jennifer L Lee, Caroline F Morrison, Sarah Drake, Ahna L Pai

{"title":"Adherence to caregiver-administered intravenous immunosuppressant medications in pediatric hematopoietic stem cell transplant.","authors":"Jennifer L Lee, Caroline F Morrison, Sarah Drake, Ahna L Pai","doi":"10.1177/10781552241258151","DOIUrl":"10.1177/10781552241258151","url":null,"abstract":"BackgroundThe purpose of this study was to describe taking, timing, and dosing adherence to home caregiver-administered intravenous (IV) immunosuppressants in a sample of pediatric hematopoietic stem cell transplant (HCT) recipients.ProceduresSixteen children who had undergone HCT, ages 3 months to 15 years, and their caregivers participated. All caregivers were biological mothers. Caregivers completed a demographic questionnaire as part of a larger study and brought in portable infusion pumps to download the pump data at the time of their child's post-HCT clinic visit. Pump data were then examined for dose taking, timing, and amount for 30 days following discharge.ResultsDespite the importance of the precise timing of IV immunosuppressants, adherence taking, dosing, and timing varied widely in this sample. The mean percentage of doses administered was 98.72%, and 81.3% of children received all doses of immunosuppressant. However, only 62% of doses were given on time and the mean difference between the prescribed and actual administration time was 67.03 minutes.ConclusionsAlthough taking adherence was high, the timing and dosing adherence to IV immunosuppressants in the home was poor. Additional support to promote adherence should be provided including assisting caregivers to identify and use adherence strategies specific to their child's IV immunosuppressant regimen in the home.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"736-743"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daratumumab desensitization: Novel approaches in POEMS syndrome experience. 达拉单抗脱敏：POEMS综合征经验的新方法。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2025-02-17 DOI: 10.1177/10781552251316477

Rosalaura Villarreal-González, Nataly Flores-García, Diana Cadenas-García, Andrés Gómez-De León, Rafael Piñeiro-Retif, Oscar Vidal-Gutiérrez

{"title":"Daratumumab desensitization: Novel approaches in POEMS syndrome experience.","authors":"Rosalaura Villarreal-González, Nataly Flores-García, Diana Cadenas-García, Andrés Gómez-De León, Rafael Piñeiro-Retif, Oscar Vidal-Gutiérrez","doi":"10.1177/10781552251316477","DOIUrl":"10.1177/10781552251316477","url":null,"abstract":"Daratumumab is a human IgG1κ monoclonal antibody targeting CD38, with infusion-related reactions occurring in 45-48% of patients. Among these, 5-10% are severe, requiring treatment discontinuation in 1% of cases. The incidence of hypersensitivity reactions (HSRs) to daratumumab is unknown. We describe a 37-year-old male diagnosed with POEMS syndrome and treated with autologous hematopoietic stem cell transplantation and chemotherapy. Presenting a relapse of the disease, intravenous daratumumab was initiated. Ten minutes after starting the first infusion, he presented with generalized rash, abdominal pain, vomiting, pharyngeal pruritus, throat tightness, dyspnea, decreased oxygen saturation, tachycardia and diaphoresis (Brown III). Due to the refractory disease and lack of alternatives, a desensitization protocol for daratumumab 1000 mg was implemented using a (3 bag-12 step) over 5.67 h. Eight successful desensitizations were performed without hypersensitivity reactions, enabling safe drug reintroduction. Currently, only one successful daratumumab desensitization protocol has been published, involving a 4-bag, 14-step procedure over 5.2 h, as reported by Carrón-Herrero et al. Prior to desensitization, the patient experienced flushing, pharyngeal pruritus, bronchospasm, dyspnea, desaturation, bradycardia, and hypotension. Both case reports were associated with severe anaphylaxis, ultimately enabling the safe reintroduction of the drug.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"846-849"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin. 低钾血症、低镁血症和低钠血症与顺铂治疗患者的急性肾损伤有关。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-07-25 DOI: 10.1177/10781552241262248

Louis Pinard, Jean-Philippe Adam, Miguel Chagnon, Guillaume Bollée, Denis Soulières

{"title":"Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin.","authors":"Louis Pinard, Jean-Philippe Adam, Miguel Chagnon, Guillaume Bollée, Denis Soulières","doi":"10.1177/10781552241262248","DOIUrl":"10.1177/10781552241262248","url":null,"abstract":"IntroductionCisplatin-associated acute kidney injury (C-AKI) is common. Predictive factors include age >60 years, hypertension, cisplatin dose, diabetes, and serum albumin < 3.5 g/L. The association between C-AKI and hypokalemia, hypomagnesemia or hyponatremia has not been well characterized.MethodsData from a previous retrospective observational study was obtained. Patients were separated into three groups with similar cisplatin doses and schedules. Group A received cisplatin 60-100 mg/m2 every three weeks with laboratory assessments before treatment, group B received cisplatin 60-75 mg/m2 every three weeks with laboratory assessments before days 1 and 8 and group C had weekly cisplatin 40 mg/m2 with weekly laboratories assessments. The association between hypomagnesemia, hypokalemia, hyponatremia, and risk of AKI was determined using a counting process specification of Cox's regression models.ResultsA total of 1301 patients were separated into groups A (n = 713), B (n = 204), and C (n = 384). The proportion of patients with at least one event of hypokalemia, hypomagnesemia, or hyponatremia was lower in group A (29.2%, 57.6%, 36.2%) compared to groups B (43.6%, 67.2%, 59.8%) and C (49.0%, 78.7%, 51.0%). The incidence of all grade C-AKI was 35.6% (group A), 46.6% (group B), and 18.2% (group C). In group A, the risk of AKI doubled with hyponatremia or hypomagnesemia and tripled with hypokalemia. This association was not seen with other groups.ConclusionAmong patients with the highest doses of cisplatin, the presence of one electrolyte disorder was associated with an increased risk of C-AKI. Other studies are needed to characterize the presence of an electrolyte disorder as a predictive risk factor of C-AKI in this subpopulation.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"754-760"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation and evaluation of busulfan pharmacokinetics in adult hematopoietic stem cell transplantation. 成体造血干细胞移植中丁硫芬药代动力学的实施与评价。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 DOI: 10.1177/10781552251352430

Julie Zhang, Cameron Ninos, Michael Reed

{"title":"Implementation and evaluation of busulfan pharmacokinetics in adult hematopoietic stem cell transplantation.","authors":"Julie Zhang, Cameron Ninos, Michael Reed","doi":"10.1177/10781552251352430","DOIUrl":"https://doi.org/10.1177/10781552251352430","url":null,"abstract":"PurposeThis study aimed to describe the implementation of busulfan pharmacokinetic (PK)-based dosing adjustments, assess the safety and efficacy of a test-dose strategy for monitoring busulfan PK, and standardize PK assessment in adult hematopoietic stem cell transplantation (HSCT).MethodsAdult patients who underwent myeloablative HSCT with PK-monitored busulfan from July 2023 to April 2024 were analyzed to assess efficacy and toxicity, including mucositis, veno-occlusive disease (VOD), engraftment, relapse, and death. The first and second therapeutic busulfan doses were determined using a test dose of 0.8 mg/kg. The area under the plasma concentration-time curve (AUC) was calculated, with a target AUC (AUCtarget) range of 4800-5300 µM*minute. The third and fourth therapeutic busulfan doses were further adjusted based on the AUC of the first dose (AUCfirst). AUCweight was calculated to predict the AUC using a weight-based strategy of 3.2 mg/kg myeloablative busulfan dose. The primary outcome was the percentage of patients achieving AUCtarget within 10%, 15%, and 20% for both AUCweight and AUCfirst.ResultsSince July 2023, a total of 13 patients have successfully undergone busulfan PK monitoring for myeloablative conditioning, achieving a 100% engraftment rate. PK-guided first dosing improved achieving the target AUC within ±10% in 63% of patients. All patients developed grade 2 or higher mucositis, with no other notable toxicities, such as VOD, reported to date.ConclusionPK-guided dosing improves target AUC achievement for adult patients undergoing myeloablative HSCT, highlighting the importance of PK monitoring for individualized patient care.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251352430"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0